{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:33:58Z","timestamp":1793579638184,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00198-022-06622-5","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:03:26Z","timestamp":1670051006000},"page":"379-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Trends in anti-osteoporotic medication utilization following fragility fracture in the USA from 2011 to 2019"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0480-9515","authenticated-orcid":false,"given":"Amil R.","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savyasachi C.","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umasuthan","family":"Srikumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Golladay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"6622_CR1","doi-asserted-by":"publisher","DOI":"10.15620\/CDC:103477","volume-title":"Osteoporosis or low bone mass in older adults: United States, 2017\u20132018. NCHS Data Brief","author":"N Sarafrazi","year":"2021","unstructured":"Sarafrazi N, Wambogo EA, Shepherd JA (2021) Osteoporosis or low bone mass in older adults: United States, 2017\u20132018. NCHS Data Brief. National Center for Health Statistics, Hyattsville. https:\/\/doi.org\/10.15620\/CDC:103477"},{"key":"6622_CR2","doi-asserted-by":"publisher","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726\u20131733.\u00a0https:\/\/doi.org\/10.1007\/s00198-006-0172-4","DOI":"10.1007\/s00198-006-0172-4"},{"issue":"3","key":"6622_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Miner Res 22(3):465\u2013475. https:\/\/doi.org\/10.1359\/jbmr.061113","journal-title":"J Bone Miner Res"},{"key":"6622_CR4","doi-asserted-by":"publisher","unstructured":"Veronese N, Kolk H, Maggi S (2021) Epidemiology of fragility fractures and social impact 19\u201334. https:\/\/doi.org\/10.1007\/978-3-030-48126-1_2","DOI":"10.1007\/978-3-030-48126-1_2"},{"key":"6622_CR5","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2106\/JBJS.N.01275","volume":"97","author":"HS Bawa","year":"2015","unstructured":"Bawa HS, Weick J, Dirschl DR (2015) Anti-osteoporotic therapy after fragility fracture lowers rate of subsequent fracture: analysis of a large population sample. J Bone Joint Surg Am 97:1555\u20131562","journal-title":"J Bone Joint Surg Am"},{"key":"6622_CR6","doi-asserted-by":"publisher","unstructured":"Osaki M, Okuda R, Saeki Y et al (2021) Efficiency of coordinator-based osteoporosis intervention in fragility fracture patients: a prospective randomized trial. Osteoporos Int 32(3):495\u2013503.\u00a0https:\/\/doi.org\/10.1007\/s00198-021-05825-6","DOI":"10.1007\/s00198-021-05825-6"},{"key":"6622_CR7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2106\/JBJS.G.01121","volume":"90","author":"TD Rozental","year":"2008","unstructured":"Rozental TD, Makhni EC, Day CS, Bouxsein ML (2008) Improving evaluation and treatment for osteoporosis following distal radial fractures. A prospective randomized intervention. J Bone Joint Surg Am 90:953\u2013961","journal-title":"J Bone Joint Surg Am"},{"key":"6622_CR8","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.2106\/JBJS.G.01246","volume":"90","author":"RA Miki","year":"2008","unstructured":"Miki RA, Oetgen ME, Kirk J, Insogna KL, Lindskog DM (2008) Orthopaedic management improves the rate of early osteoporosis treatment after hip fracture. A randomized clinical trial. J Bone Joint Surg Am 90:2346\u20132353","journal-title":"J Bone Joint Surg Am"},{"key":"6622_CR9","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.2106\/JBJS.15.01494","volume":"98","author":"AD Bunta","year":"2016","unstructured":"Bunta AD, Edwards BJ, Macaulay WBJ, Jeray KJ, Tosi LL, Jones CB, Sietsema DL, Kaufman JD, Murphy SA, Song J et al (2016) Own the bone, a system-based intervention, improves osteoporosis care after fragility fractures. J Bone Joint Surg Am 98:e109","journal-title":"J Bone Joint Surg Am"},{"key":"6622_CR10","unstructured":"What is own the bone? AOA Own the Bone. https:\/\/www.ownthebone.org\/what-is-otb\/. Published September 22,\u00a02021. Accessed 2 Dec\u00a02022"},{"issue":"2","key":"6622_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-020-05557-z","volume":"32","author":"E McCloskey","year":"2021","unstructured":"McCloskey E, Rathi J, Heijmans S et al (2021) The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int 32(2):251\u2013259. https:\/\/doi.org\/10.1007\/s00198-020-05557-z","journal-title":"Osteoporos Int"},{"key":"6622_CR12","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/jbmr.2202","volume":"29","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res Off J Am Soc Bone Miner Res 29:1929\u20131937","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"6622_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11657-016-0285-0","volume":"11","author":"AA Yusuf","year":"2016","unstructured":"Yusuf AA, Matlon TJ, Grauer A, Barron R, Chandler D, Peng Y (2016) Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries. Arch Osteoporos 11:31","journal-title":"Arch Osteoporos"},{"key":"6622_CR14","doi-asserted-by":"publisher","unstructured":"Ross BJ, Lee OC, Harris MB, Dowd TC, Savoie FH 3rd, Sherman WF (2021) Rates of osteoporosis management and secondary preventative treatment after primary fragility fractures. JB JS Open Access 6(2):e20.00142.\u00a0https:\/\/doi.org\/10.2106\/JBJS.OA.20.00142","DOI":"10.2106\/JBJS.OA.20.00142"},{"key":"6622_CR15","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.2106\/JBJS.G.00864","volume":"90","author":"V Rabenda","year":"2008","unstructured":"Rabenda V, Vanoverloop J, Fabri V, Mertens R, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster J-Y (2008) Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am 90:2142\u20132148","journal-title":"J Bone Joint Surg Am"},{"key":"6622_CR16","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.spinee.2019.10.020","volume":"20","author":"AT Malik","year":"2020","unstructured":"Malik AT, Retchin S, Phillips FM, Xu W, Peters K, Yu E, Khan SN (2020) Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and medicare advantage beneficiaries. Spine J 20:538\u2013546","journal-title":"Spine J"},{"key":"6622_CR17","doi-asserted-by":"publisher","unstructured":"Blume SW, Curtis JR (2011) Medical costs of osteoporosis in the elderly medicare population. Osteoporos Int 22(6):1835\u20131844.\u00a0https:\/\/doi.org\/10.1007\/s00198-010-1419-7","DOI":"10.1007\/s00198-010-1419-7"},{"key":"6622_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","volume":"39","author":"N Li","year":"2021","unstructured":"Li N, Cornelissen D, Silverman S, Pinto D, Si L, Kremer I, Bours S, de Bot R, Boonen A, Evers S et al (2021) An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics 39:181\u2013209","journal-title":"Pharmacoeconomics"},{"key":"6622_CR19","doi-asserted-by":"publisher","unstructured":"Mauck KF, Cuddihy MT, Trousdale RT, Pond GR, Pankratz VS, Melton LJ 3rd (2002) The decision to accept treatment for osteoporosis following hip fracture: exploring the woman\u2019s perspective using a stage-of-change model. Osteoporos Int 13(7):560\u2013564.\u00a0https:\/\/doi.org\/10.1007\/s001980200073","DOI":"10.1007\/s001980200073"},{"key":"6622_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/MED.0000000000000501","volume":"26","author":"Z Ilyas","year":"2019","unstructured":"Ilyas Z, Camacho PM (2019) Rare adverse effects of bisphosphonate therapy. Curr Opin Endocrinol Diabetes Obes 26:335\u2013338","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"6622_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/2040622310374783","volume":"1","author":"EM Lewiecki","year":"2010","unstructured":"Lewiecki EM (2010) Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis 1:115\u2013128","journal-title":"Ther Adv Chronic Dis"},{"key":"6622_CR22","first-page":"92","volume":"43","author":"KN Tu","year":"2018","unstructured":"Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, Van, (2018) K, Hyun, D: Osteoporosis: a review of treatment options. P T 43:92\u2013104","journal-title":"P T"},{"key":"6622_CR23","unstructured":"McLaughlin MB, JI (2022) Calcitonin. StatPearls; at https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537269\/. Accessed 1 Nov 2022"},{"key":"6622_CR24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/CIA.S51940","volume":"9","author":"KM Sidlauskas","year":"2014","unstructured":"Sidlauskas KM, Sutton EE, Biddle MA (2014) Osteoporosis in men: epidemiology and treatment with denosumab. Clin Interv Aging 9:593\u2013601. https:\/\/doi.org\/10.2147\/CIA.S51940","journal-title":"Clin Interv Aging"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06622-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06622-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06622-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T17:46:40Z","timestamp":1674496000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06622-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6622"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06622-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]},"assertion":[{"value":"19 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amil R. Agarwal: Declares no conflict of interests.Jordan S. Cohen: Declares no conflict of interests.Alexis Jorgensen: Declares no conflict of interests.Savyasachi C. Thakkar: KCI: unpaid consultant, Orthoalign: unpaid consultantUmasuthan Srikumaran: Arthrex Inc: financial\/material support, Depuy: financial\/material support, Fx Shoulder: paid consultant and speaker, Orthofix, Inc: Paid consultant, Quantum OPS: Stock options, ROM3: Stock options, Sonogen: Stock options, Stryker: financial\/material support, Thieme: Publishing royalties, financial\/material support, Tigon Medical: IP royalties, paid consultant, stock options, Wright Medical Technology: financial or material supportGregory J. Golladay: Stryker: IP royalties","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}